{"id":2388,"date":"2021-02-23T05:30:33","date_gmt":"2021-02-23T05:30:33","guid":{"rendered":"https:\/\/grail.com\/?post_type=press-release&p=2388"},"modified":"2021-05-20T03:05:47","modified_gmt":"2021-05-20T03:05:47","slug":"grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test","status":"publish","type":"press-release","link":"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/","title":{"rendered":"GRAIL and Quest Diagnostics Announce Collaboration to Support\u00a0Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test\u00a0\u00a0"},"content":{"rendered":"

— Quest Diagnostics to Provide Blood Specimen Collection for\u00a0Galleri\u00a0Through its Patient Service Centers and Mobile Phlebotomists —\u00a0<\/span><\/p>\n

MENLO PARK, Calif., February\u00a023, 2021 \u2013 GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced\u00a0an agreement\u00a0with Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services,\u00a0to provide phlebotomy services to support\u00a0Galleri\u2122, GRAIL\u2019s multi-cancer early detection blood test.\u00a0\u00a0<\/span><\/p>\n

Quest Diagnostics maintains approximately 2,200 patient service centers and, through its ExamOne business, 5,000 mobile phlebotomists with expertise in at-home visits. Quest\u2019s phlebotomy network will help provide blood specimen collection for\u00a0Galleri\u00a0in the United States once the test becomes available this year. \u00a0\u00a0\u00a0\u00a0<\/span><\/p>\n

\u201cToday, the majority of cancers go undetected until too late when outcomes are often deadly, and we believe\u00a0Galleri\u00a0could offer a unique and potentially life-saving solution by finding multiple types of cancers earlier,\u201d said Dr. Joshua Ofman, chief medical officer and head of external affairs at GRAIL. \u201cWe are pleased to\u00a0work\u00a0with Quest and are very encouraged by the interest in\u00a0Galleri. Our\u00a0agreement\u00a0with Quest will help us support convenient access to blood collection for patients and healthcare providers.\u201d\u00a0\u00a0<\/span><\/p>\n

\u201cQuest Diagnostics is committed to providing the broadest access to diagnostic innovation. That includes multi-cancer early detection, an important area of\u00a0oncology diagnostics\u00a0with potential to radically improve cancer screening, monitoring, and treatment,\u201d said Kristie M. Dolan, vice president and general manager, Oncology Clinical Franchise, for Quest Diagnostics. \u201cGalleri\u00a0is a\u00a0pioneer\u00a0in early detection innovation, and we are eager to support GRAIL\u2019s efforts to make it accessible to patients across the United States.\u201d\u00a0<\/span><\/p>\n

In January, GRAIL\u00a0<\/span>announced<\/span><\/a> it expects to introduce\u00a0Galleri\u00a0in the second quarter of 2021. The blood test, which will be prescription only, will be available initially through partner health systems, medical practices, and self-insured employers.<\/span><\/p>\n

An earlier version of\u00a0Galleri demonstrated the ability to detect more than 50 types of cancers \u2014 over 45 of which lack recommended screening tests today \u2014 with a low false positive rate of less than 1%. When a cancer signal is detected,\u00a0Galleri\u00a0can determine the location of the cancer signal with high accuracy, all from a single blood draw.\u00a0Galleri is intended to be used alongside standard of care screenings.<\/span><\/p>\n

Galleri\u00a0is available under investigational use in PATHFINDER, GRAIL\u2019s prospective, interventional study evaluating the implementation of\u00a0Galleri\u00a0in clinical practice.\u00a0Galleri\u00a0is also expected to be offered to eligible patients in the United Kingdom (UK) later this year as part of a partnership with the UK National Health Service to support its Long Term Plan for earlier cancer diagnoses in an effort to transform cancer outcomes.\u00a0<\/span><\/p>\n

About GRAIL<\/b>\u00a0<\/span><\/p>\n

GRAIL is a healthcare company whose mission is to detect cancer\u00a0early, when\u00a0it can be cured. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine\u2019s greatest challenges with\u00a0Galleri\u2122, GRAIL\u2019s multi-cancer early detection test. An earlier version of\u00a0Galleri\u00a0demonstrated the ability to detect more than 50 types of cancers \u2014 over 45 of which lack recommended screening tests today in the U.S. \u2014 with a low false positive rate of less than 1%. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.\u00a0<\/span><\/p>\n

About Quest Diagnostics<\/b>\u00a0<\/span><\/p>\n

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy\u00a0behaviors\u00a0and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our\u00a050,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.\u00a0<\/span>www.QuestDiagnostics.com<\/span><\/a>.\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

— Quest Diagnostics to Provide Blood Specimen Collection for\u00a0Galleri\u00a0Through its Patient Service Centers and Mobile Phlebotomists —\u00a0 MENLO PARK, Calif., February\u00a023, 2021 \u2013 GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced\u00a0an agreement\u00a0with Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services,\u00a0to provide […]<\/p>\n","protected":false},"featured_media":2327,"parent":0,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2388","press-release","type-press-release","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nGRAIL and Quest Diagnostics Announce Collaboration to Support\u00a0Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test\u00a0\u00a0 - GRAIL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GRAIL and Quest Diagnostics Announce Collaboration to Support\u00a0Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test\u00a0\u00a0 - GRAIL\" \/>\n<meta property=\"og:description\" content=\"— Quest Diagnostics to Provide Blood Specimen Collection for\u00a0Galleri\u00a0Through its Patient Service Centers and Mobile Phlebotomists —\u00a0 MENLO PARK, Calif., February\u00a023, 2021 \u2013 GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced\u00a0an agreement\u00a0with Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services,\u00a0to provide […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/\" \/>\n<meta property=\"og:site_name\" content=\"GRAIL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/grailbio\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-20T03:05:47+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/grail.com\/wp-content\/uploads\/2021\/04\/purple-vial-image.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"1068\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@grailbio\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/\",\"url\":\"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/\",\"name\":\"GRAIL and Quest Diagnostics Announce Collaboration to Support\u00a0Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test\u00a0\u00a0 - GRAIL\",\"isPartOf\":{\"@id\":\"https:\/\/grail.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/04\/purple-vial-image.png\",\"datePublished\":\"2021-02-23T05:30:33+00:00\",\"dateModified\":\"2021-05-20T03:05:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/#primaryimage\",\"url\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/04\/purple-vial-image.png\",\"contentUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/04\/purple-vial-image.png\",\"width\":1600,\"height\":1068,\"caption\":\"Medical professionals holding purple vials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/grail.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GRAIL and Quest Diagnostics Announce Collaboration to Support\u00a0Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test\u00a0\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/grail.com\/#website\",\"url\":\"https:\/\/grail.com\/\",\"name\":\"GRAIL\",\"description\":\"Detect cancer early, when it can be cured\",\"publisher\":{\"@id\":\"https:\/\/grail.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/grail.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/grail.com\/#organization\",\"name\":\"GRAIL, LLC\",\"url\":\"https:\/\/grail.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/grail.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png\",\"contentUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png\",\"width\":512,\"height\":512,\"caption\":\"GRAIL, LLC\"},\"image\":{\"@id\":\"https:\/\/grail.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/grailbio\/\",\"https:\/\/x.com\/grailbio\",\"https:\/\/www.linkedin.com\/company\/grail-inc.\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GRAIL and Quest Diagnostics Announce Collaboration to Support\u00a0Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test\u00a0\u00a0 - GRAIL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/","og_locale":"en_US","og_type":"article","og_title":"GRAIL and Quest Diagnostics Announce Collaboration to Support\u00a0Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test\u00a0\u00a0 - GRAIL","og_description":"— Quest Diagnostics to Provide Blood Specimen Collection for\u00a0Galleri\u00a0Through its Patient Service Centers and Mobile Phlebotomists —\u00a0 MENLO PARK, Calif., February\u00a023, 2021 \u2013 GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced\u00a0an agreement\u00a0with Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services,\u00a0to provide […]","og_url":"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/","og_site_name":"GRAIL","article_publisher":"https:\/\/www.facebook.com\/grailbio\/","article_modified_time":"2021-05-20T03:05:47+00:00","og_image":[{"width":1600,"height":1068,"url":"http:\/\/grail.com\/wp-content\/uploads\/2021\/04\/purple-vial-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@grailbio","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/","url":"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/","name":"GRAIL and Quest Diagnostics Announce Collaboration to Support\u00a0Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test\u00a0\u00a0 - GRAIL","isPartOf":{"@id":"https:\/\/grail.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/#primaryimage"},"image":{"@id":"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/#primaryimage"},"thumbnailUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/04\/purple-vial-image.png","datePublished":"2021-02-23T05:30:33+00:00","dateModified":"2021-05-20T03:05:47+00:00","breadcrumb":{"@id":"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/#primaryimage","url":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/04\/purple-vial-image.png","contentUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/04\/purple-vial-image.png","width":1600,"height":1068,"caption":"Medical professionals holding purple vials"},{"@type":"BreadcrumbList","@id":"https:\/\/grail.com\/press-releases\/grail-and-quest-diagnostics-announce-collaboration-to-support-galleri-first-of-kind-multi-cancer-early-detection-blood-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/grail.com\/"},{"@type":"ListItem","position":2,"name":"GRAIL and Quest Diagnostics Announce Collaboration to Support\u00a0Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test\u00a0\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/grail.com\/#website","url":"https:\/\/grail.com\/","name":"GRAIL","description":"Detect cancer early, when it can be cured","publisher":{"@id":"https:\/\/grail.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/grail.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/grail.com\/#organization","name":"GRAIL, LLC","url":"https:\/\/grail.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/grail.com\/#\/schema\/logo\/image\/","url":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png","contentUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png","width":512,"height":512,"caption":"GRAIL, LLC"},"image":{"@id":"https:\/\/grail.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/grailbio\/","https:\/\/x.com\/grailbio","https:\/\/www.linkedin.com\/company\/grail-inc.\/"]}]}},"_links":{"self":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release\/2388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/types\/press-release"}],"version-history":[{"count":0,"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release\/2388\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/media\/2327"}],"wp:attachment":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/media?parent=2388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}